NYSE:MD - MEDNAX Stock Price, Forecast & News

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

MEDNAX Inc (NYSE:MD) released its quarterly earnings results on Friday, November, 1st. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.83 by $0.08. The business had revenue of $888.70 million for the quarter, compared to analyst estimates of $876.20 million. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The company's quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the business earned $0.94 earnings per share. View MEDNAX's Earnings History.

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for MEDNAX.

MEDNAX will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 analysts have issued 12-month target prices for MEDNAX's shares. Their forecasts range from $18.00 to $34.00. On average, they anticipate MEDNAX's stock price to reach $27.73 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price. View Analyst Price Targets for MEDNAX.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Press coverage about MD stock has trended very positive on Tuesday, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEDNAX earned a coverage optimism score of 3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for MEDNAX.

Some companies that are related to MEDNAX include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), CorVel (CRVL), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Dominion Energy (D), Gilead Sciences (GILD), AbbVie (ABBV), Exxon Mobil (XOM), Chevron (CVX), Walt Disney (DIS), Pfizer (PFE), AT&T (T), Intel (INTC) and CVS Health (CVS).

MEDNAX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (6.35%), P2 Capital Partners LLC (4.63%), State Street Corp (2.59%), FMR LLC (2.02%), LSV Asset Management (1.54%) and Prudential Financial Inc. (1.52%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

MD stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Panagora Asset Management Inc., State Street Corp, Goldman Sachs Group Inc., Man Group plc, AlphaCrest Capital Management LLC and Stone Ridge Asset Management LLC. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

MD stock was purchased by a variety of institutional investors in the last quarter, including P2 Capital Partners LLC, Great Lakes Advisors LLC, LSV Asset Management, Renaissance Technologies LLC, Bank of New York Mellon Corp, William Blair Investment Management LLC, Schroder Investment Management Group and Mackay Shields LLC. View Insider Buying and Selling for MEDNAX.

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MD stock can currently be purchased for approximately $26.70.

MEDNAX has a market capitalization of $2.25 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

The official website for MEDNAX is http://www.mednax.com/.

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]